Pathologists Use Spatial Light Interference Microscopy to Predict Risk of Prostate Cancer Recurrence Prior to Biopsy or Surgery
|
By LabMedica International staff writers Posted on 24 May 2015 |

Image: Left: Quantitative phase image of an unstained prostatectomy sample from a patient who had a biochemical recurrence of prostate cancer. Right: A zoomed-in region from the quantitative phase image showing a cancerous gland with debris in the lumen. The stroma, or supportive tissue environment, shows discontinuities in the fiber length and disorganization in the orientation of the fibers (Photo courtesy of the University of Illinois).
A novel microscopy method that combines phase contrast microscopy with holography enables prediction of the likelihood of prostate cancer recurrence prior to biopsy or surgery.
The method is called spatial light interference microscopy or SLIM. SLIM uses a commercial phase contrast microscope and white light illumination, resulting in nanometer scale sensitivity to optical path-length shifts. In essence, SLIM combines phase contrast microscopy with holography.
Investigators at the University of Illinois (Urbana, USA) have introduced a new instrument for SLIM imaging. Their real-time fast SLIM technique could image at a maximum rate of 50 frames per second and provided real-time quantitative phase images at 12.5 frames per second. They were able to achieve this fast rate by combining rapid LCPM (linear pulse-code modulation) and a fast sCMOS camera. In addition, they developed the software to perform phase reconstruction and display the quantitative phase images in real-time.
In the current study, the investigators used the SLIM technique to examine 181 tissue samples obtained from the [US] National Cancer Institute-sponsored Cooperative Prostate Tissue Resource (CPCTR), The specimens were taken from individuals who had a prostatectomy, approximately half who had no recurrence and half who did.
The instrument was programmed to scan microscope slides containing 320–360 individual cores. The resulting SLIM image contained rich information about tissue morphology, with the glandular epithelium and stroma structures clearly resolved. This allowed the investigators to interrogate scattering changes specific to prostate stroma.
Results suggested that SLIM showed promise in assisting pathologists to improve prediction of prostate cancer recurrence. The data revealed that a lower value of anisotropy corresponded to a higher risk for recurrence, meaning that the stroma adjoining the glands of recurrent patients was more fractionated than in non-recurrent patients. Anisotropy is the property of being directionally dependent, as opposed to isotropy, which implies identical properties in all directions. It can be defined as a difference, when measured along different axes, in a material's physical or mechanical properties.
"For every 20 surgery procedures to take out the prostate, it is estimated that only one life is saved," said senior author Dr. Gabriel Popescu, associate professor of electrical and computer engineering at the University of Illinois. "For the other 19 people, they would be better left alone, because with removing the prostate, the quality of life goes down dramatically. So if you had a tool that could tell which patient will actually be more likely to have a bad outcome, then you could more aggressively treat that case."
"What SLIM is very good at is to make invisible objects visible with nanoscale sensitivity," said Dr. Popescu. "So we pick these structural details without the need for staining, which can introduce new variables into the specimen. Our dream is for everyone to have SLIM capabilities in their labs. One can imagine that a SLIM-based tissue imager will scan biopsies in a clinic and, paired with software that is intelligent enough to look for these specific markers, will provide the pathologist with valuable new information. This additional information will translate into more accurate diagnosis and prognosis."
The paper describing the use of SLIM to predict prostate cancer recurrence was published in the May 15, 2015, online edition of the journal Scientific Reports.
Related Links:
University of Illinois
The method is called spatial light interference microscopy or SLIM. SLIM uses a commercial phase contrast microscope and white light illumination, resulting in nanometer scale sensitivity to optical path-length shifts. In essence, SLIM combines phase contrast microscopy with holography.
Investigators at the University of Illinois (Urbana, USA) have introduced a new instrument for SLIM imaging. Their real-time fast SLIM technique could image at a maximum rate of 50 frames per second and provided real-time quantitative phase images at 12.5 frames per second. They were able to achieve this fast rate by combining rapid LCPM (linear pulse-code modulation) and a fast sCMOS camera. In addition, they developed the software to perform phase reconstruction and display the quantitative phase images in real-time.
In the current study, the investigators used the SLIM technique to examine 181 tissue samples obtained from the [US] National Cancer Institute-sponsored Cooperative Prostate Tissue Resource (CPCTR), The specimens were taken from individuals who had a prostatectomy, approximately half who had no recurrence and half who did.
The instrument was programmed to scan microscope slides containing 320–360 individual cores. The resulting SLIM image contained rich information about tissue morphology, with the glandular epithelium and stroma structures clearly resolved. This allowed the investigators to interrogate scattering changes specific to prostate stroma.
Results suggested that SLIM showed promise in assisting pathologists to improve prediction of prostate cancer recurrence. The data revealed that a lower value of anisotropy corresponded to a higher risk for recurrence, meaning that the stroma adjoining the glands of recurrent patients was more fractionated than in non-recurrent patients. Anisotropy is the property of being directionally dependent, as opposed to isotropy, which implies identical properties in all directions. It can be defined as a difference, when measured along different axes, in a material's physical or mechanical properties.
"For every 20 surgery procedures to take out the prostate, it is estimated that only one life is saved," said senior author Dr. Gabriel Popescu, associate professor of electrical and computer engineering at the University of Illinois. "For the other 19 people, they would be better left alone, because with removing the prostate, the quality of life goes down dramatically. So if you had a tool that could tell which patient will actually be more likely to have a bad outcome, then you could more aggressively treat that case."
"What SLIM is very good at is to make invisible objects visible with nanoscale sensitivity," said Dr. Popescu. "So we pick these structural details without the need for staining, which can introduce new variables into the specimen. Our dream is for everyone to have SLIM capabilities in their labs. One can imagine that a SLIM-based tissue imager will scan biopsies in a clinic and, paired with software that is intelligent enough to look for these specific markers, will provide the pathologist with valuable new information. This additional information will translate into more accurate diagnosis and prognosis."
The paper describing the use of SLIM to predict prostate cancer recurrence was published in the May 15, 2015, online edition of the journal Scientific Reports.
Related Links:
University of Illinois
Latest Pathology News
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
- AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
- Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
- AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
- AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes
- New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
- Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
- Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
- Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma
- Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
- AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
- AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
- Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
- AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Channels
Clinical Chemistry
view channel
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read more
Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read moreMolecular Diagnostics
view channel
Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests
Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more
Digital PCR Assays Support Surveillance of Bundibugyo Ebolavirus Outbreak
QIAGEN (Venlo, Netherlands) has introduced two custom-designed research-use-only (RUO) QIAcuity dPCR assays to support infectious disease research and surveillance connected to the Bundibugyo ebolavirus outbreak.... Read more
Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Immune Enzyme Linked to Treatment-Resistant Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) affects nearly 3 million people in the United States and its prevalence continues to rise. Medications that target tumor necrosis factor (TNF)-alpha are widely used, but... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read moreTechnology
view channel
Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
Colorectal cancer screening is a longstanding preventive priority, yet participation and follow-up remain uneven across patient groups. Safety‑net primary care settings often face barriers that limit screening... Read more
Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
Chronic liver disease is common and often progresses silently, increasing the risk of cirrhosis and hepatocellular carcinoma when not detected early. With an estimated 1.5 billion people affected worldwide... Read moreIndustry
view channelWerfen and Oxford Nanopore Collaborate on Transplant Assay Development
Werfen (Barcelona, Spain), a global specialized diagnostics company, has announced a strategic collaboration with Oxford Nanopore Technologies (Oxford, UK), which develops nanopore-based sequencing technology,... Read more








